Instead, PAX5‐ETV6 functions as a potent oncoprotein to promote B‐ALL development in combination with loss of the tumor suppressors Cdkn2a and Cdkn2b (Smeenk et al, 2017). This evidence concerns the gene PAX5 and acute lymphoblastic leukemia.